Loading...
  • adoptive
  • A. Tumor burden in individual PyMT ChOVA mice following adoptive transfer of 5×10 6 naïve OT-I cells (red lines, N=7) or untreated controls (black line, N=12). (nih.gov)
  • C. Cytotoxic activity of OT-I T cells isolated from the LNs (green), or tumor (red) of PyMTChOva mice 5 days after adoptive transfer, compared to in vitro activated control OT-I T cells (black line with triangles) or control OT-I lysis of unpulsed EL4s (black line with squares). (nih.gov)
  • cytotoxic
  • The availability of antitumor cytotoxic T lymphocytes which can be generated from either peripheral blood lymphocytes after stimulation in vitro or tumor infiltrating lymphocytes (TIL) has made it possible to identify a number of melanoma antigens presented by major histocompatibility complex class I molecules. (rupress.org)
  • blockade
  • Collectively, our findings support the use of Tim-3-Tim-3L blockade together with PD-1-PD-L1 blockade to reverse tumor-induced T cell exhaustion/dysfunction in patients with advanced melanoma. (nih.gov)
  • molecule
  • Traditionally, immune checkpoint molecule is not included in the tumor antigens. (hstalks.com)
  • In the presence of the relevant antigen-positive cell line, each respective DART molecule was able to promote T-cell proliferation and cytokine release in a HER2 or EphA2-dependent manner. (aacrjournals.org)
  • The present and previous studies indicated that TIL586 recognized an antigen expressed on most melanoma and normal melanocytes in the context of the HLA-A31 molecule. (rupress.org)
  • vitro
  • In vitro demonstration of humoral and cell-bound immunity against common specific transplantation atigen(s) of adenovirus 12-induced mouse and hamster tumors. (pubmedcentralcanada.ca)
  • expression
  • Spas-1 expression was increased in advanced primary TRAMP tumors. (nih.gov)
  • Spas-1 expression is not restricted to the prostate but is increased in older TRAMP tumors. (nih.gov)
  • The clinical potential of these antigens is hampered by their limited expression in ALL patients or by their restricted presentation by nonprevalent HLA alleles. (aacrjournals.org)
  • identification
  • This review will summarize multiple approaches to targeting intracellular antigens with therapeutic antibodies, in particular describing the production and characterization of TCRm antibodies, the factors influencing their target identification, their advantages and disadvantages in the context of TCR therapies, and the potential to advance TCRm-based therapies into the clinic. (frontiersin.org)
  • Clinical
  • Unique TAAs are now being frequently found in several human tumors, although their use in clinical trials is difficult for the time required to characterize unique TAAs at a single patient level ( 8 , 9 , 13 ). (aacrjournals.org)
  • recognition
  • However, while vaccines have proven to be effective in combating pathogenic microorganisms, based on the immune recognition of these foreign antigens, vaccines aimed at inducing effective antitumor activity are still unsatisfactory. (asm.org)
  • Tolerance
  • Significant improvements may result from the selection of the appropriate tumor-specific target antigen (to overcome the peripheral immune tolerance) and/or the development of immunization strategies effective at inducing a protective immune response. (asm.org)